Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial.
Bryce E HaacRobert V O'TooleTheodore T MansonGerard P SlobogeanRenan C CastilloRobert V O'TooleDeborah M Steinnull nullPublished in: PloS one (2020)
The findings of the Global Rank test suggest no evidence of superiority between LMWH or aspirin for VTE prevention in fracture patients. LMWH demonstrated a 60.5% VTE prevention benefit in the weighted time to event analysis. However, this difference did not reach statistical significance and was similar to the elicited patient preferences for aspirin.
Keyphrases
- venous thromboembolism
- low dose
- direct oral anticoagulants
- randomized controlled trial
- trauma patients
- cardiovascular events
- end stage renal disease
- antiplatelet therapy
- ejection fraction
- study protocol
- chronic kidney disease
- newly diagnosed
- magnetic resonance
- type diabetes
- prognostic factors
- case report
- peritoneal dialysis
- cardiovascular disease
- systematic review
- anti inflammatory drugs
- computed tomography
- growth factor
- contrast enhanced
- meta analyses